

BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report July 2023



© 2023 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital 687 - 1081 Burrard Street Vancouver, BC V6Z 1Y6

Tel: 604.806.8515 Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677 St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222 Website: www.bccfe.ca Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







## **EXECUTIVE SUMMARY**

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to people living with HIV throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







## TABLE OF CONTENTS

## 1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV Resistance Testing Results by Resistance Category

## 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





## Table of Contents, cont'd...

## 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

## 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

#### ABORIGINAL

4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

## 5. Appendix

5.1 Drug Names and Definitions










## 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

N = 7592



Health Authority	Male	Female	All
FRASER	1523	461	1984
INTERIOR	464	121	585
NORTHERN	149	77	226
VANCOUVER COASTAL	3324	447	3771
VANCOUVER ISLAND	832	167	999
	6292	1273	7565
		Unknown/not stated:	27
		Total:	7592

#### Definitions:

On antiretroviral therapy defined as being on treatment in the current month Unknown/not stated defined as being on treatment in the current month, and city of residence unknown Male & Female refer to Sex at birth




BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





Monthly Report



1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (July 2018 - July 2023)


## Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month




BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







Monthly Report



1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (July 2018 - July 2023)

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month




BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS






Monthly Report

in HIV/AIDS





Ministry of Health

BRITISH COLUMBIA

ALTH CARE


How you want to be treated.

Monthly Report

in HIV/AIDS

How you want to be treated.

1.5 **BC-CfE Enrolment: New Antiretroviral Participants** (July 2018 - July 2023)



Drug definitions available in the back.


Monthly Report

**CENTRE** for **EXCELLENCE** 

in HIV/AIDS

HEALTH CARE

How you want to be treated.



Ministry of Health

BRITISH COLUMBIA 1.6 Percent Distribution of Active Participants by CD4 Count (July 2018 - July 2023)


Monthly Report

**CENTRE** for **EXCELLENCE** 

in HIV/AIDS

HEALTH CARE

How you want to be treated.





Ministry of Health

BRITISH COLUMBIA 1.7 Percent Distribution of Inactive Participants by CD4 Count (July 2018 - July 2023)

Monthly Report


1.8 Active and Inactive Participants (July 2018 - July 2023)





Monthly Report

in HIV/AIDS



Ministry of Health

BRITISH COLUMBIA


HEALTH CARE

How you want to be treated.


Percent Distribution of Participants on ARV Therapy by Number of Drugs 1.9 (July 2018 - July 2023)


Monthly Report






Monthly Report





This document is best viewed in colour.

Drug definitions available in the back.



Ministry of Health

BRITISH COLUMBIA




HEALTH CARE

How you want to be treated.

Monthly Report

in HIV/AIDS



BRITISH

COLUMBIA

How you want to be treated.


1.12 **Distribution of Participants on Protease Inhibitor by INGREDIENT** (July 2018 - July 2023)


Drug definitions available in the back.

Monthly Report

in HIV/AIDS

#### 1.13 **Distribution of Participants on Protease Inhibitor** at the time of first start of ARV Therapy by INGREDIENT





BRITISH COLUMBIA


How you want to be treated.

Drug definitions available in the back.

Monthly Report

in HIV/AIDS





BRITISH COLUMBIA

How you want to be treated.


Drug definitions available in the back.

Monthly Report

in HIV/AIDS

#### 1.15 **Distribution of Participants on Non-Nucleosides** at the time of first start of ARV Therapy by INGREDIENT

(July 2018 - July 2023)




BRITISH COLUMBIA

How you want to be treated.

Monthly Report






Monthly Report



(July 2018 - July 2023)

This document is best viewed in colour.

Drug definitions available in the back.



Ministry of Health


BRITISH COLUMBIA




HEALTH CARE

How you want to be treated.

Monthly Report













Monthly Report






Monthly Report

in HIV/AIDS

How you want to be treated.

COLUMBIA

Health




1.20 **Cumulative Resistance Testing Results by Resistance Category** (July 2018 - July 2023)

Drug definitions available in the back.

Monthly Report







## 2.1 Duration of ARV treatment in the Province of BC, 1987-2023 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Curr (n)	rent CD4 Median		ent PVL Median	Current ARV Median
1987	31	4	0	4	1	880	4	<40	4
1988	32	4	0	4	1	380	4	<40	4
1989	30	48	1	49	22	500	46	<40	3
1990	28	49	1	50	26	555	48	<40	3
1991	29	37	3	40	17	520	38	<40	3
1992	29	51	3	54	21	680	49	<40	3
1993	28	115	14	129	69	560	123	<40	3
1994	26	67	12	79	42	550	71	<40	3
1995	27	117	18	135	72	560	124	<40	3
1996	24	301	48	349	183	570	319	<40	3
1997	22	261	29	290	158	595	266	<40	3
1998	22	176	38	214	122	585	194	<40	3
1999	22	142	38	180	112	600	164	<40	3
2000	22	115	28	143	77	630	121	<40	3
2001	21	109	24	133	75	620	122	<40	3
2002	20	116	23	139	84	565	130	<40	3
2003	20	131	26	157	95	590	144	<40	3
2004	19	138	38	176	111	650	164	<40	3
2005	18	169	39	208	126	658	187	<40	3
2006	17	164	42	206	116	640	187	<40	3
2007	16	225	41	266	153	640	233	<40	3
2008	15	265	58	323	196	620	289	<40	3
2009	14	289	63	352	206	640	322	<40	3
2010	13	247	66	313	182	675	283	<40	3
2011	12	317	63	380	229	680	341	<40	3
2012	11	253	61	314	174	690	284	<40	3
2013	10	251	65	316	188	690	290	<40	3
2014	9	262	46	308	174	726	281	<40	3
2015	8	258	45	303	167	720	267	<40	3
2016	7	236	49	285	156	680	243	<40	3
2017	6	195	31	226	135	680	203	<40	3
2018	5	177	47	224	134	745	199	<40	3

#### **Definitions:**

On treatment defined as being on ARV therapy in the specified month and not reported deceased **Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption **Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent) **Current ARV** defined as number of ARV drugs in the current regimen



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







## 2.1 Duration of ARV treatment in the Province of BC, 1987-2023 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All		ent CD4 Median	Curr (n)	ent PVL Median	Current ARV Median
2019	4	213	40	253	163	690	229	<40	3
2020	3	171	53	224	159	710	204	<40	3
2021	2	178	35	213	128	645	193	<40	3
2022	1	263	49	312	205	670	295	<40	3
2023	0	183	41	224	203	530	218	<40	3
Total:		6297	1278	7575					

#### **Definitions:**

On treatment defined as being on ARV therapy in the specified month and not reported deceased **Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption **Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent) **Current ARV** defined as number of ARV drugs in the current regimen



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	7465	756	1878	<40	1317	650
FEB-2022	7386	774	1803	<40	1263	620
MAR-2022	7458	766	1904	<40	1251	620
APR-2022	7420	778	1755	<40	1153	620
MAY-2022	7477	763	1998	<40	1306	620
JUN-2022	7482	759	1839	<40	1201	630
JUL-2022	7495	754	1761	<40	1141	645
AUG-2022	7492	758	1990	<40	1227	620
SEP-2022	7442	772	1787	<40	1091	640
OCT-2022	7468	778	1849	<40	1164	640
NOV-2022	7502	783	1898	<40	1201	630
DEC-2022	7545	787	1607	<40	1004	635
JAN-2023	7583	793	2051	<40	1315	650
FEB-2023	7523	807	1727	<40	1013	630
MAR-2023	7550	803	1974	<40	1208	640
APR-2023	7558	796	1761	<40	1077	630
MAY-2023	7595	786	1933	<40	1208	650
JUN-2023	7607	787	1841	<40	1057	640
JUL-2023	7592	805	1748	<40	1023	620

#### **Definitions:**

Active patient defined as being on ARV treatment in the specified month Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period) PVL and CD4 tests defined as tests done in the specified month









## 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	786	273	55	<40	45	580
FEB-2022	856	232	73	<40	56	635
MAR-2022	800	285	94	<40	73	480
APR-2022	834	278	70	<40	53	550
MAY-2022	758	317	60	<40	43	490
JUN-2022	761	291	61	<40	43	400
JUL-2022	764	283	61	<50	36	447
AUG-2022	787	261	59	78	49	560
SEP-2022	844	209	71	<40	53	460
OCT-2022	827	216	83	<40	62	495
NOV-2022	813	213	80	50	60	505
DEC-2022	777	236	57	<40	45	560
JAN-2023	737	289	63	<40	45	550
FEB-2023	790	234	66	<40	53	550
MAR-2023	759	244	78	<40	55	510
APR-2023	762	234	66	<40	47	560
MAY-2023	730	243	65	<40	45	440
JUN-2023	708	213	57	<40	38	445
JUL-2023	734	195	67	<40	49	560

#### Definitions:

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month







Monthly Report

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2022	7432	786	19	7	161	144	2	14485
FEB-2022	7371	856	8	9	151	211	-61	14510
MAR-2022	7432	800	16	9	232	160	61	14539
APR-2022	7397	834	11	1	156	178	-35	14559
MAY-2022	7450	758	13	13	205	146	53	14583
JUN-2022	7457	761	11	15	178	170	7	14620
JUL-2022	7469	764	10	13	188	176	12	14659
AUG-2022	7468	787	15	17	169	172	-1	14697
SEP-2022	7423	844	13	15	146	191	-45	14725
OCT-2022	7443	827	14	16	195	171	20	14760
NOV-2022	7480	813	9	17	210	177	37	14799
DEC-2022	7512	777	19	8	213	166	32	14826
JAN-2023	7552	737	20	10	193	143	40	14861
FEB-2023	7507	790	10	11	159	205	-45	14885
MAR-2023	7534	759	15	21	197	176	27	14919
APR-2023	7536	762	13	13	174	166	2	14948
MAY-2023	7578	730	7	15	203	165	42	14992
JUN-2023	7587	708	13	17	165	157	9	15027
JUL-2023	7575	734	10	12	164	176	-12	15059

## 2.4 BC-CfE Enrolment

**Definitions:** 

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





Monthly Report

## 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2022	499	6468	455	43	7465	6.68%	86.64%	6.10%	0.58%	100.00%
FEB-2022	525	6371	445	45	7386	7.11%	86.26%	6.02%	0.61%	100.00%
MAR-2022	550	6408	455	45	7458	7.37%	85.92%	6.10%	0.60%	100.00%
APR-2022	567	6357	450	46	7420	7.64%	85.67%	6.06%	0.62%	100.00%
MAY-2022	597	6381	452	47	7477	7.98%	85.34%	6.05%	0.63%	100.00%
JUN-2022	614	6376	450	42	7482	8.21%	85.22%	6.01%	0.56%	100.00%
JUL-2022	634	6371	445	45	7495	8.46%	85.00%	5.94%	0.60%	100.00%
AUG-2022	643	6365	441	43	7492	8.58%	84.96%	5.89%	0.57%	100.00%
SEP-2022	663	6295	439	45	7442	8.91%	84.59%	5.90%	0.60%	100.00%
OCT-2022	679	6309	439	41	7468	9.09%	84.48%	5.88%	0.55%	100.00%
NOV-2022	696	6318	446	42	7502	9.28%	84.22%	5.95%	0.56%	100.00%
DEC-2022	709	6345	449	42	7545	9.40%	84.10%	5.95%	0.56%	100.00%
JAN-2023	721	6373	445	44	7583	9.51%	84.04%	5.87%	0.58%	100.00%
FEB-2023	735	6320	429	39	7523	9.77%	84.01%	5.70%	0.52%	100.00%
MAR-2023	750	6314	445	41	7550	9.93%	83.63%	5.89%	0.54%	100.00%
APR-2023	765	6311	441	41	7558	10.12%	83.50%	5.83%	0.54%	100.00%
MAY-2023	801	6318	435	41	7595	10.55%	83.19%	5.73%	0.54%	100.00%
JUN-2023	821	6307	438	41	7607	10.79%	82.91%	5.76%	0.54%	100.00%
JUL-2023	845	6267	440	40	7592	11.13%	82.55%	5.80%	0.53%	100.00%

#### **Definitions:**

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





Monthly Report

2.6	Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT
-----	---

[		lamiv	udine		abacavir					zidov	udine		te	nofovi	r <taf< th=""><th>-&gt;</th><th colspan="4">tenofovir <tdf></tdf></th><th></th><th>emtric</th><th>itabine</th><th>•</th></taf<>	->	tenofovir <tdf></tdf>					emtric	itabine	•
	Initia	al	All		Init	ial	All		Initi	al	All		Init	ial	All		Init	ial	All		Init	ial	All	I
JAN-2022	3	20%	3064	42%	3	20%	2480	34%	0	0%	19	0%	12	80%	2922	40%	0	0%	1473	20%	12	80%	4262	58%
FEB-2022	6	24%	3019	42%	3	12%	2410	33%	2	8%	19	0%	15	60%	2939	41%	4	16%	1395	19%	19	76%	4225	58%
MAR-2022	3	10%	3034	41%	2	7%	2406	33%	0	0%	19	0%	24	83%	3029	41%	2	7%	1350	18%	26	90%	4272	58%
APR-2022	4	20%	3019	41%	3	15%	2366	33%	0	0%	19	0%	14	70%	3052	42%	2	10%	1313	18%	16	80%	4250	58%
MAY-2022	4	17%	3026	41%	3	13%	2354	32%	0	0%	18	0%	17	74%	3145	43%	2	9%	1282	17%	19	83%	4309	59%
JUN-2022	5	14%	3015	41%	0	0%	2309	31%	0	0%	19	0%	29	81%	3199	44%	4	11%	1237	17%	31	86%	4320	59%
JUL-2022	4	10%	3007	41%	3	8%	2285	31%	0	0%	19	0%	27	69%	3229	44%	9	23%	1218	17%	35	90%	4343	59%
AUG-2022	5	14%	2991	41%	4	11%	2261	31%	0	0%	18	0%	29	78%	3271	45%	3	8%	1178	16%	32	86%	4353	59%
SEP-2022	4	14%	2952	40%	3	11%	2195	30%	0	0%	17	0%	19	68%	3284	45%	5	18%	1173	16%	24	86%	4352	60%
OCT-2022	6	17%	2950	40%	4	11%	2173	30%	0	0%	16	0%	29	83%	3350	46%	0	0%	1143	16%	29	83%	4388	60%
NOV-2022	7	18%	2948	40%	5	13%	2158	29%	0	0%	15	0%	26	68%	3387	46%	6	16%	1136	15%	31	82%	4417	60%
DEC-2022	4	15%	2952	40%	3	11%	2149	29%	1	4%	16	0%	18	67%	3446	47%	5	19%	1109	15%	23	85%	4445	60%
JAN-2023	6	17%	2972	40%	1	3%	2148	29%	1	3%	16	0%	23	66%	3491	47%	8	23%	1096	15%	29	83%	4466	60%
FEB-2023	3	13%	2945	40%	1	4%	2098	28%	0	0%	17	0%	18	75%	3502	47%	3	13%	1066	14%	21	88%	4447	60%
MAR-2023	2	6%	2937	40%	2	6%	2072	28%	0	0%	15	0%	27	79%	3551	48%	5	15%	1052	14%	32	94%	4477	60%
APR-2023	3	10%	2951	40%	1	3%	2070	28%	0	0%	15	0%	24	83%	3551	48%	3	10%	1031	14%	26	90%	4471	60%
MAY-2023	10	24%	2942	39%	4	10%	2045	27%	1	2%	16	0%	30	71%	3599	48%	3	7%	1041	14%	32	76%	4515	61%
JUN-2023	4	12%	2936	39%	1	3%	2010	27%	0	0%	14	0%	26	76%	3658	49%	4	12%	1005	13%	30	88%	4539	61%
JUL-2023	5	16%	2923	39%	1	3%	1971	26%	0	0%	14	0%	25	78%	3682	49%	3	9%	990	13%	27	84%	4539	61%

**Definitions:** 

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS



BRITISH COLUMBIA **CENTRE** for **EXCELLENCE** in HIV/AIDS



Ministry of

Monthly Report

[	fo	samp	renavi	r		ataza	navir			daru	inavir			lopir	navir			ritor	navir			tiprar	navir	
	Initi	al	All		Init	tial	All		Ini	tial	Al		Init	ial	All		Initi	al	All		Initi	al	All	
JAN-2022	0	0%	1	0%	0	0%	476	29%	0	0%	1132	68%	0	0%	60	4%	0	0%	1	0%	0	0%	1	0%
FEB-2022	0	0%	1	0%	1	33%	447	28%	1	33%	1110	69%	1	33%	60	4%	0	0%	1	0%	0	0%	1	0%
MAR-2022	0	0%	1	0%	0	0%	430	27%	2	100%	1113	70%	0	0%	57	4%	0	0%	1	0%	0	0%	1	0%
APR-2022	0	0%	1	0%	0	0%	424	27%	0	0%	1085	69%	0	0%	56	4%	0	0%	1	0%	0	0%	1	0%
MAY-2022	0	0%	1	0%	1	33%	417	27%	2	67%	1080	70%	0	0%	53	3%	0	0%	1	0%	0	0%	1	0%
JUN-2022	0	0%	1	0%	0	0%	407	27%	1	100%	1056	70%	0	0%	52	3%	0	0%	1	0%	0	0%	1	0%
JUL-2022	0	0%	1	0%	0	0%	405	27%	1	100%	1039	70%	0	0%	50	3%	0	0%	1	0%	0	0%	1	0%
AUG-2022	0	0%	1	0%	0	0%	385	26%	1	100%	1028	71%	0	0%	45	3%	0	0%	1	0%	0	0%	1	0%
SEP-2022	0	0%	0	0%	0	0%	367	26%	2	100%	1010	71%	0	0%	44	3%	0	0%	1	0%	0	0%	1	0%
OCT-2022	0	0%	0	0%	0	0%	354	25%	0	0%	1002	72%	0	0%	44	3%	0	0%	1	0%	0	0%	1	0%
NOV-2022	0	0%	0	0%	0	0%	352	25%	6	100%	995	72%	0	0%	43	3%	0	0%	1	0%	0	0%	1	0%
DEC-2022	0	0%	0	0%	0	0%	342	25%	1	100%	1008	72%	0	0%	45	3%	0	0%	1	0%	0	0%	1	0%
JAN-2023	0	0%	0	0%	0	0%	339	25%	1	100%	994	72%	0	0%	44	3%	0	0%	1	0%	0	0%	1	0%
FEB-2023	0	0%	0	0%	0	0%	321	24%	0	0%	954	73%	0	0%	43	3%	0	0%	1	0%	0	0%	1	0%
MAR-2023	0	0%	0	0%	0	0%	317	24%	1	100%	953	73%	0	0%	42	3%	0	0%	1	0%	0	0%	1	0%
APR-2023	0	0%	0	0%	0	0%	305	23%	1	100%	959	74%	0	0%	42	3%	0	0%	1	0%	0	0%	1	0%
MAY-2023	0	0%	0	0%	0	0%	304	23%	2	100%	953	74%	0	0%	40	3%	0	0%	1	0%	0	0%	1	0%
JUN-2023	0	0%	0	0%	0	0%	296	23%	0	0%	938	74%	0	0%	39	3%	0	0%	1	0%	0	0%	1	0%
JUL-2023	0	0%	0	0%	0	0%	284	23%	3	100%	929	74%	0	0%	38	3%	0	0%	1	0%	0	0%	1	0%

## 2.7 Number of Participants on Protease Inhibitor by INGREDIENT

#### **Definitions:**

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



Ministry of

Health

Monthly Report

		dora	virine			efav	irenz		etravirine					nevira	apine		rilpivirine			
	Init	ial	All		Init	tial	All		Initi	al	All		Init	tial	All		Init	ial	All	
JAN-2022	0	0%	103	9%	0	0%	328	30%	0	0%	130	12%	0	0%	317	29%	0	0%	235	21%
FEB-2022	0	0%	106	10%	0	0%	317	29%	0	0%	127	12%	0	0%	306	28%	1	100%	228	21%
MAR-2022	0	0%	113	11%	1	100%	303	28%	0	0%	132	12%	0	0%	301	28%	0	0%	222	21%
APR-2022	1	50%	124	12%	1	50%	301	28%	0	0%	130	12%	0	0%	297	28%	0	0%	223	21%
MAY-2022	0	0%	136	13%	0	0%	287	27%	0	0%	128	12%	0	0%	290	27%	1	100%	220	21%
JUN-2022	1	33%	149	14%	1	33%	284	27%	0	0%	122	12%	0	0%	285	27%	1	33%	211	20%
JUL-2022	0	0%	155	15%	1	33%	280	27%	0	0%	117	11%	0	0%	280	27%	2	67%	207	20%
AUG-2022	0	0%	157	15%	1	33%	275	27%	0	0%	119	12%	0	0%	274	27%	2	67%	204	20%
SEP-2022	0	0%	167	16%	3	100%	271	27%	0	0%	110	11%	0	0%	273	27%	0	0%	200	20%
OCT-2022	0	0%	173	17%	0	0%	261	26%	0	0%	105	10%	0	0%	269	27%	0	0%	196	20%
NOV-2022	1	33%	183	18%	2	67%	261	26%	0	0%	108	11%	0	0%	269	26%	0	0%	197	19%
DEC-2022	0	0%	186	19%	1	25%	254	25%	0	0%	107	11%	1	25%	262	26%	2	50%	195	19%
JAN-2023	3	43%	192	19%	4	57%	247	25%	0	0%	107	11%	0	0%	255	26%	0	0%	191	19%
FEB-2023	0	0%	202	20%	0	0%	250	25%	0	0%	98	10%	0	0%	249	25%	0	0%	190	19%
MAR-2023	0	0%	209	21%	0	0%	242	25%	0	0%	101	10%	0	0%	246	25%	0	0%	186	19%
APR-2023	1	50%	215	22%	1	50%	232	24%	0	0%	96	10%	0	0%	245	25%	0	0%	187	19%
MAY-2023	1	33%	223	23%	0	0%	232	24%	0	0%	98	10%	0	0%	239	24%	2	67%	187	19%
JUN-2023	0	0%	225	24%	3	75%	228	24%	0	0%	96	10%	0	0%	230	24%	1	25%	180	19%
JUL-2023	0	0%	235	25%	2	100%	224	23%	0	0%	94	10%	0	0%	225	24%	0	0%	178	19%

## 2.8 Number of Participants on Non-Nucleosides by INGREDIENT

#### **Definitions:**

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



BRITISH e treated. COLUMBIA Ministry of Health

Monthly Report

	bictegravir			cabotegravir				dolutegravir				elvitegravir				fostemsavir				maraviroc				raltegravir			
	Initial All		Init	Initial All			Initial		All		Initial		All		Initial All		All		Initial		All		Initial		All		
JAN-2022	11	73%	2421 43%	0	0%	0	0%	2	13%	2468	44%	1	7%	347	6%	0	0%	0	0%	0	0%	24	0%	1	7%	374	7%
FEB-2022	15	71%	2443 44%	0	0%	0	0%	6	29%	2437	44%	0	0%	331	6%	0	0%	0	0%	0	0%	21	0%	0	0%	369	7%
MAR-2022	23	85%	2536 45%	0	0%	0	0%	3	11%	2460	43%	1	4%	324	6%	0	0%	0	0%	0	0%	21	0%	0	0%	370	7%
APR-2022	14	74%	2574 45%	0	0%	0	0%	5	26%	2436	43%	0	0%	312	5%	0	0%	0	0%	0	0%	20	0%	0	0%	366	6%
MAY-2022	17	77%	2666 46%	0	0%	0	0%	5	23%	2455	43%	0	0%	309	5%	0	0%	0	0%	0	0%	22	0%	0	0%	360	6%
JUN-2022	29	85%	2710 47%	0	0%	0	0%	5	15%	2454	42%	0	0%	300	5%	0	0%	0	0%	0	0%	22	0%	0	0%	352	6%
JUL-2022	24	69%	2745 47%	0	0%	0	0%	7	20%	2452	42%	3	9%	297	5%	0	0%	0	0%	0	0%	22	0%	1	3%	342	6%
AUG-2022	26	76%	2790 48%	0	0%	0	0%	6	18%	2452	42%	1	3%	294	5%	0	0%	0	0%	1	3%	22	0%	1	3%	340	6%
SEP-2022	19	76%	2820 48%	0	0%	0	0%	6	24%	2433	42%	0	0%	281	5%	0	0%	0	0%	0	0%	21	0%	0	0%	323	6%
OCT-2022	28	80%	2889 49%	0	0%	0	0%	6	17%	2440	41%	1	3%	280	5%	0	0%	0	0%	0	0%	22	0%	0	0%	314	5%
NOV-2022	24	73%	2920 49%	0	0%	0	0%	8	24%	2462	41%	1	3%	276	5%	0	0%	1	0%	0	0%	22	0%	0	0%	309	5%
DEC-2022	16	70%	2974 50%	0	0%	0	0%	5	22%	2465	41%	1	4%	270	4%	0	0%	1	0%	0	0%	20	0%	1	4%	307	5%
JAN-2023	23	82%	3016 50%	0	0%	0	0%	5	18%	2493	41%	0	0%	269	4%	0	0%	1	0%	0	0%	21	0%	0	0%	302	5%
FEB-2023	18	75%	3040 50%	0	0%	0	0%	6	25%	2477	41%	0	0%	255	4%	0	0%	1	0%	0	0%	21	0%	0	0%	288	5%
MAR-2023	25	74%	3084 51%	0	0%	0	0%	5	15%	2483	41%	2	6%	259	4%	0	0%	1	0%	0	0%	20	0%	2	6%	291	5%
APR-2023	22	81%	3085 50%	0	0%	0	0%	4	15%	2499	41%	1	4%	258	4%	0	0%	1	0%	0	0%	18	0%	0	0%	275	5%
MAY-2023	28	67%	3139 51%	1	2%	3	0%	12	29%	2504	41%	1	2%	250	4%	0	0%	1	0%	0	0%	18	0%	0	0%	279	5%
JUN-2023	26	81%	3199 51%	0	0%	5	0%	6	19%	2510	40%	0	0%	249	4%	0	0%	1	0%	0	0%	18	0%	0	0%	268	4%
JUL-2023	25	83%	3221 52%	0	0%	5	0%	5	17%	2502	40%	0	0%	248	4%	0	0%	1	0%	0	0%	18	0%	0	0%	258	4%

Ministry of

#### **Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS



BRITISH COLUMBIA **CENTRE** for **EXCELLENCE** in HIV/AIDS



# 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

		sted PI						s from lasses	≥ 3 drug			Other
MON-YYYY	+ 2 N n	(t)RTIs %	+ 2 N n	(t)RTIs %	+ 2 N n	(t)RTIs %	n	%	≥ sc n	lasses %	n	%
JAN-2022	985	13.19	773	10.35	4452	59.64	496	6.64	673	9.02	86	1.15
FEB-2022	958	12.97	750	10.15	4409	59.69	522	7.07	667	9.03	80	1.08
MAR-2022	934	12.52	737	9.88	4482	60.10	548	7.35	673	9.02	84	1.13
APR-2022	908	12.24	725	9.77	4473	60.28	565	7.61	669	9.02	80	1.08
MAY-2022	898	12.01	709	9.48	4527	60.55	595	7.96	668	8.93	80	1.07
JUN-2022	873	11.67	705	9.42	4558	60.92	612	8.18	658	8.79	76	1.02
JUL-2022	857	11.43	698	9.31	4578	61.08	632	8.43	654	8.73	76	1.01
AUG-2022	828	11.05	691	9.22	4610	61.53	641	8.56	648	8.65	74	0.99
SEP-2022	799	10.74	691	9.29	4575	61.48	662	8.90	641	8.61	74	0.99
OCT-2022	788	10.55	673	9.01	4620	61.86	678	9.08	636	8.52	73	0.98
NOV-2022	770	10.26	682	9.09	4639	61.84	694	9.25	645	8.60	72	0.96
DEC-2022	774	10.26	663	8.79	4681	62.04	706	9.36	650	8.61	71	0.94
JAN-2023	751	9.90	665	8.77	4729	62.36	718	9.47	648	8.55	72	0.95
FEB-2023	716	9.52	665	8.84	4713	62.65	733	9.74	625	8.31	71	0.94
MAR-2023	700	9.27	653	8.65	4736	62.73	748	9.91	643	8.52	70	0.93
APR-2023	706	9.34	653	8.64	4738	62.69	762	10.08	634	8.39	65	0.86
MAY-2023	709	9.34	644	8.48	4753	62.58	799	10.52	626	8.24	64	0.84
JUN-2023	679	8.93	626	8.23	4792	62.99	819	10.77	626	8.23	65	0.85
JUL-2023	666	8.77	628	8.27	4766	62.78	843	11.10	627	8.26	62	0.82

#### Definitions:

n is number of participants on the specified regimen class in the specified month
% is ratio of n and total number of participants on ART in the specified month
Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





### 2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2022	7	1	0	1	1	3	490
FEB-2022	9	0	1	0	1	5	530
MAR-2022	9	4	1	1	1	2	150
APR-2022	1	0	0	0	0	1	820
MAY-2022	13	4	1	1	1	6	490
JUN-2022	15	1	4	1	4	4	400
JUL-2022	13	1	4	3	2	2	225
AUG-2022	17	1	3	3	2	5	330
SEP-2022	15	1	0	3	6	4	405
OCT-2022	16	0	0	1	5	9	520
NOV-2022	17	1	2	2	5	6	445
DEC-2022	8	1	1	2	0	1	320
JAN-2023	10	2	2	2	2	2	285
FEB-2023	11	2	2	3	1	3	253
MAR-2023	21	0	0	4	3	11	530
APR-2023	13	1	3	1	1	5	440
MAY-2023	15	2	1	2	5	2	374
JUN-2023	17	2	4	3	2	6	340
JUL-2023	12	1	2	4	2	3	265

#### **Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive) **Baseline CD4** is defined as most recent CD4 test before ARV start







## 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Partcipants with PVL test, and never on ART	
JAN-2022	12277	3734	
FEB-2022	12300	3748	
MAR-2022	12328	3763	
APR-2022	12357	3788	
MAY-2022	12348	3777	
JUN-2022	12363	3779	
JUL-2022	12389	3788	
AUG-2022	12410	3800	
SEP-2022	12429	3809	
OCT-2022	12455	3829	
NOV-2022	12463	3819	
DEC-2022	12440	3801	
JAN-2023	12448	3803	
FEB-2023	12436	3788	
MAR-2023	12443	3787	
APR-2023	12418	3753	
MAY-2023	12426	3731	
JUN-2023	12400	3693	
JUL-2023	12428	3716	

#### **Definitions:**

Patients with PVL test are defined as having at leat one PVL test within previous five years, and not reported deceased/moved Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month










**3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7592** Jul-2023




BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





**3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant** Jul-2023

#### INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS






**3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant** Jul-2023










BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant Jul-2023

### VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



**Distribution of HIV/AIDS Drug Treatment Program Active Participant** 3.5 Jul-2023


#### VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



How you want to be treated.



**3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant** Jul-2023



#### NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA

BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





# 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

		•	Ever	Currently
HSDA	Age Group	Alive	treated with ARVs	treated with ARVs
EAST KOOTENAY	20-34	*	*	*
KUUTENAT	35-49			
	50+	*	*	*
	Total HSDA:	45	61	28
KOOTENAY	0-19	*	*	*
BOUNDARY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	73	101	53
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	441	599	329
THOMPSON/CARIBOO/	0-19	*	*	*
SHUSWAP	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	235	318	175
Total HA:		794	1079	585
			Ever	Currently
	Age Group	Alive	treated with ARVs	treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		794	1079	585
			Ever	Currently
Sex at Birth		Alive	treated with ARVs	treated with ARVs
Female		163	221	121
Male		631	858	464
Currently treated with AR	Vs	# of patients	Med Age	Med CD4 Med PVL
Total HA:		585	56	670 <40

#### \* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

#### **Definitions:**

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





# 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

Total HA:		794	585
	<5 years	136	110
	5 years or more	161	113
	10 years or more	497	362
	Treatment Duration	Alive	Currently treated with ARVs
Total HA:		794	585
	Total HSDA:	235	175
	<5 years	45	36
SHUSWAP	5 years or more	45	30
THOMPSON/CARIBOO/	10 years or more	145	109
	Total HSDA:	441	329
	<5 years	73	57
KANAGAN	5 years or more	88	65
OKANAGAN	10 years or more	280	207
	Total HSDA:	73	53
	<5 years	12	11
BOUNDARY	5 years or more	13	10
KOOTENAY	10 years or more	48	32
	Total HSDA:	45	28
	<5 years	6	6
KOOTENAY	5 years or more	15	8
EAST	10 years or more	24	14
HSDA	Duration	Alive	treated with ARVs
	Treatment		Currently

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

**Currently treated with ARVs** defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







# 4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	52	70	11	13
KOOTENAY BOUNDARY	79	138	19	42
OKANAGAN	239	1086	52	339
THOMPSON/CARIBOO/SHUSWAR	P 150	569	33	143
Total:	520	1863	115	537

HSDA of	# of Patients seeking Prescriber's care	
Patient Residency	out of HA	
EAST KOOTENAY	12	
KOOTENAY BOUNDARY	12	
OKANAGAN	70	
THOMPSON/CARIBOO/SHU	SWAP 48	
Total:	142	

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

#### **Definitions:**

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months # of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





# 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	5
	20-34	38	40	31
	35-49	100	102	66
	50+	267	371	196
	Total HSDA:	412	520	298
FRASER NORTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	1150	1558	868
FRASER SOUTH	0-19	9	9	9
	20-34	109	111	79
	35-49	301	327	235
	50+	626	959	495
	Total HSDA:	1045	1406	818
	Total HODA.	1040		
Total HA:	Total HobA	2607	3484	1984
Total HA:				
Total HA:	Age Group		3484	1984
Total HA:	I	2607	3484 Ever	1984 Currently
Total HA:	Age Group	2607 Alive	3484 Ever treated with ARVs	1984 Currently treated with ARVs
Total HA:	Age Group 0-19	2607 Alive 17	3484 Ever treated with ARVs 17	1984 Currently treated with ARVs 15
Total HA:	Age Group 0-19 20-34	2607 Alive 17 285	3484 Ever treated with ARVs 17 290	1984 Currently treated with ARVs 15 207
Total HA:	Age Group 0-19 20-34 35-49	2607 Alive 17 285 762	3484 Ever treated with ARVs 17 290 816	1984 Currently treated with ARVs 15 207 575
	Age Group 0-19 20-34 35-49	2607 Alive 17 285 762 1543	3484 Ever treated with ARVs 17 290 816 2361	1984Currently treated with ARVs1520757511871984
	Age Group 0-19 20-34 35-49	2607 Alive 17 285 762 1543	3484 Ever treated with ARVs 17 290 816 2361 3484	1984 Currently treated with ARVs 15 207 575 1187
Total HA:	Age Group 0-19 20-34 35-49	2607 Alive 17 285 762 1543 2607	3484 Ever treated with ARVs 17 290 816 2361 3484 Ever	1984 Currently treated with ARVs 15 207 575 1187 1984 Currently
Total HA: Sex at Birth	Age Group 0-19 20-34 35-49	2607 Alive 17 285 762 1543 2607 Alive	3484 Ever treated with ARVs 17 290 816 2361 3484 Ever treated with ARVs	1984 Currently treated with ARVs 15 207 575 1187 1984 Currently treated with ARVs
Total HA: Sex at Birth Female	Age Group 0-19 20-34 35-49 50+	2607 Alive 17 285 762 1543 2607 Alive 631	3484 Ever treated with ARVs 17 290 816 2361 3484 Ever treated with ARVs 807	1984Currently treated with ARVs1520757511871984Currently treated with ARVs461

#### \* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







# 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

	Treatment		Currently
HSDA	Duration	Alive	treated with ARVs
FRASER EAST	10 years or more	279	207
	5 years or more	63	35
	<5 years	70	56
	Total HSDA:	412	298
FRASER NORTH	10 years or more	715	518
	5 years or more	239	188
	<5 years	196	162
	Total HSDA:	1150	868
FRASER SOUTH	10 years or more	642	493
	5 years or more	209	160
	<5 years	194	165
	Total HSDA:	1045	818
Total HA:	1	2607	1984
	Treatment		Currently
	Duration	Alive	treated with ARVs
	10 years or more	1636	1218
	5 years or more	511	383
	<5 years	460	383
Total HA:		2607	1984

### \* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

**Currently treated with ARVs** defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation









### 4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	150	542	31	62
FRASER NORTH	261	1627	43	222
FRASER SOUTH	227	1809	48	488
Total:	638	3978	122	772

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA	
FRASER EAST	202	
FRASER NORTH	713	
FRASER SOUTH	473	
Total:	1388	

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

#### **Definitions:**

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

# of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





# 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth VANCOUVER COASTAL Health Authority

HSDA     Age Group     Alive     treated with ARVs     treated with ÂRVs       NORTH SHORE/     0-19     *     *     *     *       20-34     *     *     *     *     *       20-34     *     *     *     *     *       20-34     *     *     *     *     *       20-34     *     *     *     *     *       50+     *     *     *     *     *       Total HSDA:     354     526     276     *       RICHMOND     20-34     29     30     18     *       35-49     61     62     48     *     *       S0+     120     176     97     *     *     *       ANCOUVER     0-19     13     13     12     *     *     *     *     *     *     *     *     *     *     *     *     *     *     *     *     *     *     *				Ever	Currently	
COAST GARIBALDI     20-34     *     *     *       35-49     *     *     *     *       50+     *     *     *     *       Total HSDA:     354     526     276       RICHMOND     20-34     29     30     18       35-49     61     62     48       50+     120     176     97       Total HSDA:     210     268     163       /ANCOUVER     0-19     13     13     12       /ANCOUVER     0-19     13     13     12       /ANCOUVER     0-19     13     33.2     14       /ANCOUVER     0-19     13     33.2     14       Total HSDA:     4686     7198     3332     14       Total HA:     5250     7992     3771     15       Age Group     Alive     treated with ARVs     treated with ARVs     14       0-19     14     14     13     13     12       20-34 <t< td=""><td>HSDA</td><td>Age Group</td><td>Alive</td><td></td><td></td><td></td></t<>	HSDA	Age Group	Alive			
35-49     * <td>NORTH SHORE/</td> <td>0-19</td> <td>*</td> <td>*</td> <td>*</td> <td></td>	NORTH SHORE/	0-19	*	*	*	
50+     *     *     *       Total HSDA:     354     526     276       RICHMOND     20-34     29     30     18       35-49     61     62     48       50+     120     176     97       Total HSDA:     210     268     163       /ANCOUVER     0-19     13     13     12       20-34     446     460     301     35-49     1235     1376     876       35-49     1235     1376     876     50+     2992     5349     2143       Total HSDA:     4686     7198     3332     50+     2992     3771       Fotal HA:     5250     7992     3771     50+     364     5942     2444       13     1368     1517     978     50+     3364     5942     2444       Fotal HA:     5250     7992     3771     50+     3364     5942     2444       Sex at Birth     Alive     treated with ARVs <td< td=""><td>COAST GARIBALDI</td><td>20-34</td><td>*</td><td>*</td><td>*</td><td></td></td<>	COAST GARIBALDI	20-34	*	*	*	
Total HSDA:     354     526     276       RICHMOND     20-34     29     30     18       35.49     61     62     48       50+     120     176     97       Total HSDA:     210     268     163       /ANCOUVER     0-19     13     13     12       20-34     446     460     301     35-49       20-34     446     460     301     35-49       20-34     446     460     301     35-49       35-49     1235     1376     876     56       50+     2992     5349     2143     54       Total HSDA:     4686     7198     3332     54       Fotal HA:     5250     7992     3771     54       Age Group     Alive     treated with ARVs     treated with ARVs     50+       0-19     14     14     13     36     35-49     3364     5942     2444       Fotal HA:     5250     7992     <		35-49	*	*	*	
RICHMOND     20-34     29     30     18       35-49     61     62     48       50+     120     176     97       Total HSDA:     210     268     163       VANCOUVER     0-19     13     13     12       20-34     446     460     301       35-49     1235     1376     876       50+     2992     5349     2143       Total HSDA:     4686     7198     3332       Total HSDA:     4686     7198     3332       Total HA:     5250     7992     3771       Xage Group     Alive     treated with ARVs     treated with ARVs       0-19     14     14     13       20-34     504     519     336       35-49     1368     1517     978       50+     3364     5942     2444       Total HA:     5250     7992     3771       Sex at Birth     Alive     treated with ARVs     treated with ARVs		50+	*	*	*	
$\begin{tabular}{ c c c c c } \hline 35.49 & 61 & 62 & 48 \\ \hline 50+ & 120 & 176 & 97 \\ \hline \end{tabular} \en$		Total HSDA:	354	526	276	
$\begin{tabular}{ c c c c c c } \hline \hline 50+ & 120 & 176 & 97 \\ \hline \hline Total HSDA: & 210 & 268 & 163 \\ \hline \mbox{VANCOUVER} & 0-19 & 13 & 13 & 12 \\ 20-34 & 446 & 460 & 301 \\ 35-49 & 1235 & 1376 & 876 \\ 50+ & 2992 & 5349 & 2143 \\ \hline \mbox{Total HSDA:} & 4686 & 7198 & 3332 \\ \hline \mbox{Total HSDA:} & 4686 & 7198 & 3332 \\ \hline \mbox{Total HA:} & 5250 & 7992 & 3771 \\ \hline \end{tabular} \end{tabular} \begin{tabular}{ c c c } \hline \mbox{Age Group} & Alive & treated with ARVs & treated with ARVs \\ \hline \mbox{Total HA:} & 504 & 519 & 336 \\ \hline \mbox{35-49} & 1368 & 1517 & 978 \\ \hline \mbox{50+} & 3364 & 5942 & 2444 \\ \hline \mbox{Total HA:} & 5250 & 7992 & 3771 \\ \hline \end{tabular} \end{tabular} \end{tabular} \end{tabular} \begin{tabular}{ c c c c c } \hline \mbox{Total HA:} & 5250 & 7992 & 3771 \\ \hline \mbox{Total HA:} & 5250 & 7992 & 3771 \\ \hline \mbox{Female} & 50+ & 3364 & 5942 & 2444 \\ \hline \mbox{Total HA:} & 5250 & 7992 & 3771 \\ \hline \end{tabular} \end{tabular} \end{tabular} \begin{tabular}{ c c c c c c c } \hline \mbox{Female} & 595 & 969 & 447 \\ \hline \mbox{Male} & & 4653 & 7021 & 3324 \\ \hline \end{tabular} \end{tabular} \begin{tabular}{ c c c c c c c c c c } \hline \mbox{Total HA:} & 595 & 969 & 447 \\ \hline \mbox{Male} & & 4653 & 7021 & 3324 \\ \hline \end{tabular} \end{tabular} \begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	RICHMOND	20-34	29	30	18	
Total HSDA:210268163VANCOUVER0-1913131220-3444646030135-491235137687650+299253492143Total HSDA:468671983332Fotal HA:Fotal HA:6 for the second sec		35-49	61	62	48	
VANCOUVER     0-19     13     13     12       20-34     446     460     301       35-49     1235     1376     876       50+     2992     5349     2143       Total HSDA:     4686     7198     3332       Fotal HA:     5250     7992     3771       Age Group     Alive     treated with ARVs     treated with ARVs       0-19     14     14     13       20-34     504     519     336       35-49     1368     1517     978       35-49     1368     1517     978       50+     3364     5942     2444       Fotal HA:     5250     7992     3771       Sex at Birth     Alive     treated with ARVs     treated with ARVs       Female     595     969     447       Wale     4653     7021     3324		50+	120	176	97	
20-34     446     460     301       35-49     1235     1376     876       50+     2992     5349     2143       Total HSDA:     4686     7198     3332       Total HSDA:     4686     7198     3332       Total HA:     5250     7992     3771       Age Group     Alive     treated with ARVs     treated with ARVs       0-19     14     14     13       20-34     504     519     336       35-49     1368     1517     978       50+     3364     5942     2444       Total HA:     5250     7992     3771       Sex at Birth     Alive     Ever     Currently treated with ARVs       Sex at Birth     Alive     Sex at Birth     Alive     Ever     Currently treated with ARVs       Genale     595     969     447     3324		Total HSDA:	210	268	163	
35-49     1235     1376     876       50+     2992     5349     2143       Total HSDA:     4686     7198     3332       Fotal HA:     5250     7992     3771       Age Group     Alive     Ever treated with ARVs     Currently treated with ARVs       0-19     14     14     13       20-34     504     519     336       35-49     1368     1517     978       50+     3364     5942     2444       Total HA:     5250     7992     3771       Sex at Birth     Alive     Ever     Currently treated with ARVs       Female     595     969     447       Male     4653     7021     3324	VANCOUVER	0-19	13	13	12	
50+     2992     5349     2143       Total HSDA:     4686     7198     3332       Total HA:     5250     7992     3771       Age Group     Alive     treated with ARVs     treated with ARVs       0-19     14     14     13       20-34     504     519     336       35-49     1368     1517     978       50+     3364     5942     2444       Total HA:     5250     7992     3771       Sex at Birth     Alive     treated with ARVs     treated with ARVs       Alive     treated with ARVs     treated with ARVs     treated with ARVs       Gex at Birth     Alive     treated with ARVs     treated with ARVs       Alive     4653     7021     3324		20-34	446	460	301	
Total HSDA:     4686     7198     3332       Fotal HA:     5250     7992     3771       Age Group     Alive     treated with ARVs     treated with ARVs       0-19     14     14     13       20-34     504     519     336       35-49     1368     1517     978       50+     3364     5942     2444       Fotal HA:     5250     7992     3771       Sex at Birth     Alive     Ever     Currently treated with ARVs       Female     595     969     447       Male     4653     7021     3324		35-49	1235	1376	876	
Fotal HA:     5250     7992     3771       Age Group     Alive     Ever     Currently treated with ARVs     Currently treated with ARVs       0-19     14     14     13       20-34     504     519     336       35-49     1368     1517     978       50+     3364     5942     2444       Fotal HA:     5250     7992     3771       Sex at Birth     Alive     treated with ARVs     treated with ARVs       Female     595     969     447       Male     4653     7021     3324		50+	2992	5349	2143	
Age Group     Alive     Ever treated with ARVs     Currently treated with ARVs       0-19     14     14     13       20-34     504     519     336       35-49     1368     1517     978       50+     3364     5942     2444       Fotal HA:     5250     7992     3771       Sex at Birth     Alive     treated with ARVs     treated with ARVs       Female     595     969     447       Male     4653     7021     3324		Total HSDA:	4686	7198	3332	
Age Group     Alive     treated with ARVs     treated with ÂRVs       0-19     14     14     13       20-34     504     519     336       35-49     1368     1517     978       50+     3364     5942     2444       Fotal HA:     5250     7992     3771       Sex at Birth     Alive     treated with ARVs     treated with ARVs       Female     595     969     447       Male     4653     7021     3324	Total HA:		5250	7992	3771	
0-19     14     14     13       20-34     504     519     336       35-49     1368     1517     978       50+     3364     5942     2444       Fotal HA:     5250     7992     3771       Sex at Birth     Alive     treated with ARVs     treated with ARVs       Female     595     969     447       Male     4653     7021     3324				Ever	Currently	
20-34   504   519   336     35-49   1368   1517   978     50+   3364   5942   2444     Total HA:   5250   7992   3771     Sex at Birth   Alive   treated with ARVs   treated with ARVs     Female   595   969   447     Male   4653   7021   3324		Age Group	Alive	treated with ARVs	treated with ARVs	
35-49   1368   1517   978     50+   3364   5942   2444     Total HA:   5250   7992   3771     Sex at Birth   Alive   Ever treated with ARVs   Currently treated with ARVs     Female   595   969   447     Male   4653   7021   3324		0-19	14	14	13	
50+336459422444Total HA:525079923771Sex at BirthAliveEverCurrently treated with ARVsFemale595969447Male465370213324		20-34	504	519	336	
Total HA:525079923771Sex at BirthEverCurrentlyFemale595969447Male465370213324		35-49	1368	1517	978	
EverCurrentlySex at BirthAlivetreated with ARVstreated with ARVsFemale595969447Male465370213324		50+	3364	5942	2444	
Sex at BirthAlivetreated with ARVstreated with ARVsFemale595969447Male465370213324	Total HA:		5250	7992	3771	
Female     595     969     447       Male     4653     7021     3324				Ever	Currently	
Male 4653 7021 3324	Sex at Birth		Alive	treated with ARVs	treated with ARVs	
	Female		595	969	447	
Jnknown 2 2 0	Male		4653	7021	3324	
	Unknown		2	2	0	
Currently treated with ARVs # of patients Med Age Med CD4 Med PVL	Currently treated with AF	RVs				-
Fotal HA:     3771     55     650     <40	Total HA:		3771	55	650 <40	

#### \* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







# 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/	10 years or more	243	193
COAST GARIBALDI	5 years or more	54	44
	<5 years	57	39
	Total HSDA:	354	276
RICHMOND	10 years or more	125	94
	5 years or more	37	27
	<5 years	48	42
	Total HSDA:	210	163
VANCOUVER	10 years or more	3271	2255
	5 years or more	792	577
	<5 years	623	500
	Total HSDA:	4686	3332
Total HA:		5250	3771
	Treatment		Currently
	Duration	Alive	treated with ARVs
	10 years or more	3639	2542
	5 years or more	883	648
	<5 years	728	581
Total HA:		5250	3771

### \* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

**Currently treated with ARVs** defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation









# 4.9 Distribution of ARV Prescribers in BC-CfE Registries VANCOUVER COASTAL Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBAL	DI 188	417	39	52
RICHMOND	45	316	8	96
VANCOUVER	688	11746	216	5455
Total:	921	12479	263	5603

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA	
NORTH SHORE/COAST GAR	IBALDI *	
RICHMOND	*	
VANCOUVER	*	
Total:	69	

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

#### **Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months **# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





# 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth VANCOUVER ISLAND Health Authority

			Ever	Currently	
HSDA	Age Group	Alive	treated with ARVs	treated with ARVs	
CENTRAL	0-19	*	*	*	
VANCOUVER	20-34	*	*	*	
ISLAND	35-49	*	*	*	
	50+	*	*	*	
	Total HSDA:	357	523	281	
NORTH	0-19	*	*	*	
VANCOUVER	20-34	*	*	*	
ISLAND	35-49	*	*	*	
	50+	*	*	*	
	Total HSDA:	129	181	105	
SOUTH	20-34	68	74	45	
VANCOUVER	35-49	195	219	148	
ISLAND	50+	546	870	420	
	Total HSDA:	809	1163	613	
Total HA:		1295	1867	999	
			Ever	Currently	
	Age Group	Alive	treated with ARVs	treated with ARVs	
	0-19	*	*	*	
	20-34	*	*	*	
	35-49	*	*	*	
	50+	*	*	*	
Total HA:		1295	1867	999	
			Ever	Currently	
Sex at Birth		Alive	treated with ARVs	treated with ARVs	
Female		216	316	167	
Male		1079	1551	832	
Currently treated with AR	RVs	# of patients	Med Age	Med CD4 Med PV	′L
Total HA:		999	56	600 <40	

#### \* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)







# 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

	Treatment		Currently
HSDA	Duration	Alive	treated with ARVs
CENTRAL	10 years or more	221	177
VANCOUVER	5 years or more	74	49
ISLAND	<5 years	62	55
	Total HSDA:	357	281
NORTH	10 years or more	92	75
VANCOUVER	5 years or more	24	18
ISLAND	<5 years	13	12
	Total HSDA:	129	105
SOUTH	10 years or more	501	368
VANCOUVER	5 years or more	158	122
ISLAND	<5 years	150	123
	Total HSDA:	809	613
Total HA:	L	1295	999
	Treatment		Currently
	Duration	Alive	treated with ARVs
	10 years or more	814	620
	5 years or more	256	189
	<5 years	225	190
Total HA:		1295	999

### \* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

**Currently treated with ARVs** defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation









# 4.12 Distribution of ARV Prescribers in BC-CfE Registries VANCOUVER ISLAND Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	204	931	68	169
NORTH VANCOUVER ISLAND	160	285	39	71
SOUTH VANCOUVER ISLAND	225	1951	38	589
Total:	589	3167	145	829

HSDA of	# of Patients seeking Prescriber's care	
Patient Residency	out of HA	
CENTRAL VANCOUVER ISL	AND 109	
NORTH VANCOUVER ISLAM	ND 45	
SOUTH VANCOUVER ISLAN	ID 124	
Total:	278	

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

#### **Definitions:**

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

# of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





# 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth NORTHERN Health Authority

			Ever	Currently	
HSDA	Age Group	Alive	treated with ARVs	treated with ARVs	
NORTH EAST	20-34	8	8	5	
	35-49	16	20	12	
	50+	29	37	15	
	Total HSDA:	53	65	32	
NORTH WEST	20-34	*	5	0	
	35-49	*	38	17	
	50+	*	77	34	
	Total HSDA:	72	120	51	
NORTHERN INTERIOR	0-19	*	*	*	
	20-34	*	*	*	
	35-49	*	*	*	
	50+	*	*	*	
	Total HSDA:	198	298	143	
Total HA:		323	483	226	
			Ever	Currently	
	Age Group	Alive	treated with ARVs	treated with ARVs	
	0-19	*	*	*	
	20-34	*	*	*	
	35-49	*	*	*	
	50+	*	*	*	
Total HA:		323	483	226	
			Ever	Currently	
Sex at Birth		Alive	treated with ARVs	treated with ARVs	
Female		115	176	77	
Male		208	307	149	
Currently treated with AR	Vs	# of patients	Med Age	Med CD4 Med PV	L

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)









# 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration NORTHERN Health Authority

	Treatment		Currently
HSDA	Duration	Alive	treated with ARVs
NORTH EAST	10 years or more	31	*
	5 years or more	6	*
	<5 years	16	*
	Total HSDA:	53	32
NORTH WEST	10 years or more	51	34
	5 years or more	11	9
	<5 years	10	8
	Total HSDA:	72	51
NORTHERN INTERIOR	10 years or more	109	80
	5 years or more	54	38
	<5 years	35	25
	Total HSDA:	198	143
Total HA:		323	226
	Treatment		Currently
	Duration	Alive	treated with ARVs
	10 years or more	191	128
	5 years or more	71	50
	<5 years	61	48
Total HA:		323	226

### \* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

**Currently treated with ARVs** defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation









# 4.15 Distribution of ARV Prescribers in BC-CfE Registries NORTHERN Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	41	61	6	8
NORTH WEST	88	181	16	40
NORTHERN INTERIOR	123	506	24	191
Total:	252	748	46	239

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA	
NORTH EAST	5	
NORTH WEST	21	
NORTHERN INTERIOR	14	
Total:	40	

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

#### **Definitions:**

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

# of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





НА	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	Aiive *	10	*
	KOOTENAY BOUNDARY	*	9	*
	OKANAGAN	*	52	*
	THOMPSON/CARIBOO/SHUSWAP	*	51	*
	Total HA:	67	122	47
FRASER	FRASER EAST	37	52	29
	FRASER NORTH	51	94	38
	FRASER SOUTH	79	116	52
	Total HA:	167	262	119
VANCOUVER	NORTH SHORE/COAST GARIBALDI	25	52	24
COASTAL	RICHMOND	6	11	5
	VANCOUVER	455	910	368
	Total HA:	486	973	397
VANCOUVER	CENTRAL VANCOUVER ISLAND	47	82	39
ISLAND	NORTH VANCOUVER ISLAND	15	29	12
	SOUTH VANCOUVER ISLAND	49	96	40
	Total HA:	111	207	91
NORTHERN	NORTH EAST	10	14	5
	NORTH WEST	32	68	20
	NORTHERN INTERIOR	72	120	53
	Total HA:	114	202	78
Total:		945	1766	732

### 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	345	632	271
Male	600	1134	461
Currently treated with ARVs	# of patients	Med Age	Med CD4 Med PVL
Total:	732	54	540 <40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:** 

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





### 5.1 Drug Names and Definitions

Abacavir: a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Antiretroviral:** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla:** the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**Cabenuva:** the ViiV Healthcare trade name for a injectable formulation containing CABOTEGRAVIR and RILPIVIRINE.

Cabotegravir: an INTEGRASE INHIBITOR.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicistat:** a pharmacokinetic enhancer ("booster") given with other antiretrovirals to improve drug exposure. Cobistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy**: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Complera: the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased**: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

**Descovy:** the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.









Didanosine (Videx): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay): an INTEGRASE INHIBITOR from ViiV Healthcare.

**Doravirine:** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir:** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine:** a NUCLEOSIDE ANALOG from Gilead Sciences. It its currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intelence):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fostemsavir: an ATTACHMENT INHIBITOR from ViiV Healthcare. Fostemsavir is a PRODRUG of TEMSAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya:** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa: the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine: a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.


**Maraviroc (Celsentri):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.









Monthly Report

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART)**: the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept): a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are preactivated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Odefsey: the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix: the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







Raltegravir (Isentress): an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure ("booster").

Stavudine (Zerit): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild:** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq: the ViiV Healthcare's trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir: the ViiV Healthcare's trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada: the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.





